New insider activity at Insmed ( (INSM) ) has taken place on June 4, 2025.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Several key executives at Insmed have recently sold shares of the company’s stock. CMO Martina M.D. Flammer sold 1,686 shares for a total of $120,549. COO Roger Adsett parted with 1,860 shares, amounting to $132,990. CFO Sara Bonstein sold 1,579 shares, bringing in $112,898. Chief People Strategy Officer Orlov Nicole Schaeffer sold 1,642 shares for $117,403. Lastly, CLO Michael Alexander Smith sold 1,448 shares, totaling $103,532.
Recent Updates on INSM stock
In the last 24 hours, Insmed has experienced notable developments, primarily driven by its strong financial performance and promising clinical advancements. Jefferies initiated coverage with a positive outlook due to Insmed’s ‘first-in-disease status’ and the potential of its brensocatib drug as a ‘megablockbuster’ treatment for bronchiectasis. The company’s Q1 2025 earnings report highlighted a 23% increase in revenue for ARIKAYCE, alongside significant progress in clinical programs, including the Phase 3 ASPEN trial for brensocatib. Despite a net loss, Insmed maintains a robust cash position, supporting its strategic focus on expanding ARIKAYCE’s commercialization and preparing for brensocatib’s potential launch. Analysts have adjusted price targets, reflecting optimism about Insmed’s growth prospects, driven by anticipated FDA approvals and strategic pipeline developments.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s stock score is driven by financial challenges and valuation concerns despite positive earnings call outcomes and supportive corporate events. Revenue growth and clinical advancements are offset by high debt and cash flow deficits.
To see Spark’s full report on INSM stock, click here.
More about Insmed
YTD Price Performance: 4.47%
Average Trading Volume: 2,252,944
Technical Sentiment Signal: Buy
Current Market Cap: $13.06B